Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors

Arthritis Rheumatol. 2022 Feb;74(2):365-366. doi: 10.1002/art.41977. Epub 2022 Jan 4.

Authors

Dimitra Dimopoulou¹, Nikos Spyridis¹, George Vartzelis¹, Maria N Tsolia¹, Despoina N Maritsi¹

Affiliation

¹ National and Kapodistrian University of Athens and Children's Hospital "Panagioti and Aglaia Kyriakou", Athens, Greece.

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / therapeutic use
Adolescent
Antirheumatic Agents / therapeutic use
Arthralgia / chemically induced
Arthritis, Juvenile / drug therapy*
BNT162 Vaccine / adverse effects*
BNT162 Vaccine / therapeutic use
COVID-19 / prevention & control*
Disease Progression
Etanercept / therapeutic use
Fatigue / chemically induced
Female
Headache / chemically induced
Humans
Injection Site Reaction / etiology
Male
Methotrexate / therapeutic use
Myalgia / chemically induced
SARS-CoV-2
Tumor Necrosis Factor Inhibitors / therapeutic use*
Young Adult

Substances

Antirheumatic Agents
Tumor Necrosis Factor Inhibitors
Adalimumab
BNT162 Vaccine
Etanercept
Methotrexate